Health

Professor Padmanabhan, Health News, ET Health World

New Delhi: India may need a third Covid vaccine by mid-next year, said prominent scientist and biochemist Professor G. Padmanaban. This is due to the prevalence of breakthrough cases, albeit mostly mild, after complete vaccination.

Professor Padmanavan, president of Tamil Nadu Central University and recipient of Padma Boushan, said his opinion on the third dose was based on “scientific understanding.”

“Infection with widespread delta mutants reduces the likelihood that antisera from the vaccine will neutralize the mutant 6-8 times compared to wild-type (used for vaccination spikes or the entire virus). ..

“No one has a clear answer yet about the duration of the protective antibody. It is estimated to be between 6 months and 1 year. If the virus does not weaken naturally, it can be re-infected by that time. There is sex. Infectious disease. “

In the case of Covid, scientists’ understanding of cell-mediated immunity (cell-mediated immunity and humoral immunity) is still evolving, so “the third mix-and-match administration (mid-to-late next year) is also different. Gives the opportunity to give. A vaccine against mutants. “

The US Centers for Disease Control and Prevention has SARS-CoV-2 RNA or antigens in respiratory specimens collected from people who have completed all recommended doses of Covid-19 for vaccine breakthrough infections more than 14 days ago. Is defined as detection of. vaccination.

Worldwide, many studies and scientists claim that two doses of the Covid vaccine are sufficient to prevent infection, hospitalization, and death from the SARS-CoV-2 virus.

However, according to the World Health Organization, the Deltacovid variant, which now spans more than 185 countries, has renewed the discussion of Covid boosters. Israel was one of the first countries to fully inoculate (twice) the majority of its population, but suffered severely due to Delta variants. It was once again one of the first countries to deploy a third dose for its citizens.

“As far as variants are concerned, delta variants are not the end of the story. The bigger question is whether you have vaccines for all the variants that are created. Probably not. So I feel by the middle of the next year. , India may need a third vaccination. “

Many countries have deployed Covid boosters, including the United States, United Kingdom, France and Germany, but India is still considering the need.

Scientists at the Indian Medical Research Council (ICMR) have not yet approved booster immunization in India. In the case of India, booster doses are not a central theme at this time, and obtaining two doses remains a top priority, media reports said ICMR director Balram Burgava said. ..

The countries that deployed the booster first gave a third dose, primarily to the elderly, 70 years and older, and to people with a weakened immune system. However, Indian experts say that there is no need for booster immunization in India because there is not enough research on this subject.

Padmanavan said: “This is essentially a case of supply and demand. We have not yet made enough to immunize for more than 18 years. 1.5 billion doses (2 jabs) to a population of Rs 7.5 billion. Needs. Probably 25 percent (2 doses).

“If this population needs to be vaccinated by December, it should be vaccinated at least 300 million times a month.”

There are currently four vaccines in India: Kovacin, Kobishield, Sputnik V and ZyCoV-D. However, vaccine production for Sputnik and Zydaskadira needs to be “scaled up”.

The other two vaccines expected in India are the mRNA vaccine by Gennova Biopharma, a subsidiary of Pune-based Emcure Pharmaceuticals, and the recombinant RBD vaccine by Biological E and Hyderabad.

“If all this becomes a reality, hopefully we can vaccinate a population of Rs 7.5 billion by March (two vaccinations). A third vaccination over the age of 70 is Only then can it be considered. During that time, children between the ages of 2 and 18 have become another segment. Public health professionals must decide. “

In his opinion, an 83-year-old scientist said, “The SARS-CoV-2 virus has weakened and is likely to be mild, if any, in the presence of a third wave.”

But, like the flu virus, the possibility of SARS-CoV-2 visiting us each year is only a “guess” at this stage, he said.

“This little virus has challenged scientists, despite claiming great advances in science and technology. It’s a lesson of humility!” He said.



Professor Padmanabhan, Health News, ET Health World

Source link Professor Padmanabhan, Health News, ET Health World

Related Articles

Back to top button